AI-generated summary
In this mouse study, the authors tested 654 nm deep red light therapy given for 12 hours daily over ten weeks in obese, diabetic db/db mice and compared them with untreated mice. They report that the treatment prevented two early markers of retinal deterioration, delayed electroretinogram b-wave latencies and elevated IBA1 expression, but had no effect on other measures. The authors note the treatment was well tolerated and call for further optimization.
- Who or what was studied
- Transgenic LepRdb/J (db/db) mice modeling type 2 diabetes, aged 33 weeks at assessment, compared with untreated mice
- Wavelengths
- 654 nm
- Limits stated in the abstract
- The study was conducted in a mouse model, the abstract does not state a sample size, and the authors indicate the therapeutic settings require further optimization.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Diabetic retinopathy is a prevalent complication of type 2 diabetes mellitus, characterized by progressive damage to the retinal structure and function. Photobiomodulation therapy, using red or near-infrared light, has been proposed as a non-invasive intervention to mitigate retinal damage, but has been tested generally with short-term stimuli. This study aimed to evaluate the effects of prolonged photobiomodulation with deep red light on retinal structure and function in a type 2 diabetes mouse model. Transgenic LepRdb/J (db/db) mice were exposed to photobiomodulation therapy via LED devices emitting 654 nm light for 12 h daily over ten weeks and compared to untreated mice. Retinal function was evaluated by flash electroretinography, while structural changes were assessed through histology and immunohistochemistry to detect astro- and microgliosis. At 33 weeks of age, db/db mice were obese and severely diabetic, but exhibited only incipient indicators of retinal deterioration. Electroretinogram b-wave peak latencies were prolonged at intermediate flash intensities, while the outer plexiform layer displayed significantly elevated IBA1 expression. Photobiomodulation therapy prevented these two markers of early retinal deterioration but had no effect on other morphological and functional parameters. Photobiomodulation is well-tolerated and maintains potential as a complementary treatment option for diabetic retinopathy but requires further optimization of therapeutic settings and combinatory treatment approaches.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 654 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Light-emitting diode, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.